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Introduction
In mammals, defi  nitive erythropoiesis fi  rst occurs in the fetal 
liver with progenitor cells from the yolk sac (Palis et al., 1999). 
Within the fetal liver and the adult bone marrow, hematopoietic 
cells are formed continuously from a small population of plu-
ripotent stem cells that generate progenitors committed to one 
or a few hematopoietic lineages. In the erythroid lineage, the 
earliest committed progenitors identifi  ed ex vivo are the slowly 
proliferating burst-forming unit–erythroids (BFU-Es; Gregory 
and Eaves, 1977, 1978). Early BFU-E cells divide and further 
differentiate through the mature BFU-E stage into rapidly di-
viding colony-forming unit–erythroids (CFU-Es; Gregory and 
Eaves, 1977, 1978). CFU-E progenitors divide three to fi  ve 
times over 2–3 d as they differentiate and undergo many sub-
stantial changes, including a decrease in cell size, chromatin 
condensation, and hemoglobinization, leading up to the enucle-
ation and expulsion of other organelles (Fawcett, 1997).
Erythropoietin (Epo) has long been understood to be the 
major factor governing erythropoiesis; its role in regulating the 
expansion, differentiation, apoptosis, and activation of erythroid-
specifi  c genes is well characterized (Richmond et al., 2005). 
The fi  rst phase of erythroid differentiation is highly Epo depen-
dent, whereas later stages are no longer dependent on Epo 
(Koury and Bondurant, 1988). Consistent with this, Epo recep-
tors are lost as erythroid progenitors undergo terminal prolifera-
tion and differentiation (Zhang et al., 2003). This raises the 
question of what other signals, if any, these differentiating 
erythroblasts require to support terminal proliferation, differen-
tiation, and enucleation. The extracellular matrix protein fi  bro-
nectin has been identifi  ed as an important part of the erythroid 
niche in both the adult bone marrow and fetal liver (Tada et al., 
2006), but its precise role in erythropoiesis and potential inter-
action with Epo-mediated signals is unknown.
Fibronectin is a ubiquitous extracellular matrix molecule 
that presents developmental cues to many cell types, including 
hematopoietic cells (Hynes, 1990 ). Interactions with fi  bronectin 
are essential for proper erythropoiesis, as adhesion to fi  bronectin 
is required for the enucleation of murine erythroleukemia cells 
(Patel and Lodish, 1987). Human bone marrow erythroid pro-
genitor cells expand in the presence of fi  bronectin in a dose-
 dependent manner and do not form enucleated erythroid colonies 
in the absence of fi  bronectin (Weinstein et al., 1989). Collec-
tively, these fi  ndings suggest that fi  bronectin not only provides 
a supportive niche for erythroid progenitor cells but also plays 
a role in ensuring proper terminal expansion and differentiation.
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rythropoietin (Epo) is essential for the terminal 
proliferation and differentiation of erythroid progen-
itor cells. Fibronectin is an important part of the 
erythroid niche, but its precise role in erythropoiesis is 
unknown. By culturing fetal liver erythroid progenitors, we 
show that ﬁ  bronectin and Epo regulate erythroid prolifera-
tion in temporally distinct steps: an early Epo-dependent 
phase is followed by a ﬁ  bronectin-dependent phase. In 
each phase, Epo and ﬁ  bronectin promote expansion by 
preventing apoptosis partly through bcl-xL. We show that 
α4, α5, and β1 are the principal integrins expressed on 
erythroid progenitors; their down-regulation during erythro-
poiesis parallels the loss of cell adhesion to ﬁ  bronectin. 
Culturing erythroid progenitors on recombinant ﬁ  bronectin 
fragments revealed that only substrates that engage 
α4β1-integrin support normal proliferation. Collectively, 
these data suggest a two-phase model for growth factor and 
extracellular matrix regulation of erythropoiesis, with an 
early Epo-dependent, integrin-independent phase followed 
by an Epo-independent, α4β1-integrin–dependent phase.
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Fibronectin is a large multidomain glycoprotein that con-
tains binding sites for heparin, collagen, fi  brin, and gelatin in 
addition to a number of cell surface receptors. Adhesion of 
hematopoietic cells to fi  bronectin is mediated by at least two 
integrin pairs. α5β1 integrin (VLA-5) mediates adhesion to the 
canonical RGDS sequence in the 10th type III repeat. There are 
two cell-binding sequences in the type III connecting segment 
that mediate adhesion to α4β1 integrin (VLA-4). The LDV se-
quence forms a high affi  nity binding site, whereas the REDV 
sequence forms a binding site with much lower affi  nity (Humphries 
et al., 1986; Komoriya et al., 1991).
α4 integrins appear to be essential for the effi  cient differ-
entiation and expansion of erythroid progenitors in vivo and 
in vitro. Deletion of α4 integrin has no effect on the number of 
fetal liver erythroid progenitors but results in decreased num-
bers of differentiated erythroid cells. In in vitro erythropoiesis 
assays, fetal liver α4-null erythroid cells formed only small pale 
colonies, whereas wild-type cells transmigrated beneath the 
stroma, expanded, and formed large red colonies (Arroyo et al., 
1999). Early studies have shown that fetal liver erythroid cells 
express both α4 and α5 integrins and that these integrins mediate 
attachment of the CFU-E to fi  bronectin and stromal cells (Vuillet-
Gaugler et al., 1990; Rosemblatt et al., 1991; Verfaillie et al., 
1994). However, the biological signifi  cance of this adhesion is 
not yet known.
In this study, we sought to characterize the precise role 
that fi  bronectin plays in erythropoiesis by using an in vitro 
model of fetal erythropoiesis (Zhang et al., 2003). In this  system, 
populations of erythroid progenitors at varying phases of dif-
ferentiation can be purifi  ed from the fetal liver based on ex-
pression of the cell surface markers CD71 and TER119; these 
same markers can then be used to track the differentiation of 
progenitor cells cultured in vitro. We present data to support 
a novel model for erythropoiesis wherein Epo and fi  bronectin 
each play a distinct, essential role. We show that erythroid ex-
pansion proceeds in two phases, with an early Epo-dependent 
phase followed by a fi  bronectin-dependent phase. We also deter-
mine that α4β1 integrin is the primary molecular mediator of the 
observed fi  bronectin response and that signals emanating from 
α4β1 engagement by fi  bronectin act to protect cells from apop-
tosis in a manner similar to the binding of Epo to its receptor.
Results
Erythroid expansion proceeds 
in temporally distinct Epo and 
ﬁ  bronectin-mediated phases
We used murine fetal liver cells to study erythroid differentia-
tion. As previously described, fetal liver erythroid cells can be 
separated into fi  ve distinct populations of progressively differ-
entiated cells based on the expression of CD71, the transferrin 
receptor, and TER119, an erythroid-specifi  c glycoprotein (Fig. 
1 A; Zhang et al., 2003). Early erythroid progenitors (the R1 
population) express moderate levels of CD71 and are TER119
−. 
Later progenitor cells (R2) express higher levels of CD71 but 
are still TER119
−. As cells continue to divide and differentiate, 
TER119 expression is induced, and CD71 expression is down-
regulated, as indicated by the R3, R4, and R5 populations. R3–5 
populations contain no CFU-E activity.
The expression of CD71 and TER119 can also be used to 
track erythroid differentiation in vitro. In this system, purifi  ed 
embryonic day (E) 14.5 TER119
− progenitor cells are cultured 
Figure 1.  CD71 and TER119 can be used as markers of erythroid differentiation in vivo and in vitro. (A) Five populations of sequentially differentiated 
erythroid cells can be isolated from day 14.5 fetal liver based on the expression of CD71 and TER119 as previously described (Zhang et al., 2003). (B) CD71 
and TER119 can be used as markers of erythroid differentiation in vitro. Day 14.5 TER119
− fetal liver cells were cultured on ﬁ  bronectin-coated plates in 
Epo-containing media for 1 d and in Epo-free media for an additional 2 d. On each day, cells were dissociated and stained with antibodies to CD71 and 
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on fi  bronectin-coated plates in two phases: fi  rst in the presence 
of Epo for 16–18 h and then without Epo for an additional 24 h. 
On each day, cells are dissociated with PBS containing EDTA, 
counted, and stained with CD71 and TER119 antibodies for 
FACS analysis. In the fi  rst phase, CD71 is up-regulated, and 
there is a modest expansion in cell number. By day 3, TER119 
is up-regulated, and CD71 is down-regulated (Fig. 1 B).
We used this in vitro model to study the role of fi  bronectin 
in erythropoiesis. We observed a dramatic increase in cell num-
ber between days 1 and 2 for TER119
− progenitor cells cultured 
on fi  bronectin but not on uncoated substrates despite the pres-
ence of Epo between days 0 and 1 in both cases (Fig. 2). As pre-
viously shown, the withdrawal of Epo during the fi  rst day of 
culture leads to an expansion defect even in the presence of 
fi  bronectin (Fig. 2, dashed lines).
This result led us to hypothesize that Epo and fi  bronectin 
regulate erythroid expansion in temporally distinct regimes. To 
test this hypothesis, we varied the presentation of extracellular 
matrix and growth factor cues during the course of the 2-d cul-
ture period. When TER119
− erythroid progenitors were cultured 
on a control substrate for 1 d and were transferred to a fi  bronectin 
substrate for the second day, the level of expansion was indistin-
guishable from that achieved in the presence of fi  bronectin for 
the entire 2-d period, suggesting that fi  bronectin is only required 
during the second day of erythroid culture (Fig. 3 A). In another 
test, we isolated TER119
+ cells from the fetal liver. As described 
previously, TER119 is a marker of differentiated erythroid cells 
(Kina et al., 2000), so we hypothesized that the expansion of 
these cells is fi  bronectin but not Epo dependent. Indeed, when 
we cultured differentiated TER119
+ erythroid cells, we found 
that they expanded on fi  bronectin and not on the control sub-
strate and that the addition of Epo had no effect (Fig. 3 B). It is 
important to note that these freshly isolated TER119
+ cells have 
not been exposed to Epo ex vivo, and, thus, the response can 
be attributed solely to the presence of fi  bronectin. Collectively, 
these results suggest a two-phase model for erythroid expansion 
in which the presence of Epo on the fi  rst day of culture followed 
by the presence of fi  bronectin on the second day of culture is 
each essential for proper erythroid expansion.
Fibronectin protects from apoptosis 
in the second phase of erythroid expansion
It is well known that Epo protects early erythroid progenitors 
from apoptosis, (Socolovsky et al., 1999) so we tested the hy-
pothesis that fi  bronectin acts in a similar manner. First, we ex-
amined the roles of Epo and fi  bronectin in preventing the 
apoptosis of early erythroid progenitors in the first phase 
of erythropoiesis. We found that nearly 40% of TER119
− cells 
  cultured overnight on fi  bronectin in the absence of Epo were 
  annexin V positive (Fig. 4 A). When Epo was present in the cul-
ture medium, the percentage of annexin V–positive cells dropped 
to 23.6%, confi  rming that Epo plays an antiapoptotic as well as 
proliferative role during the fi  rst phase of erythropoiesis. How-
ever, the absence of fi  bronectin either in the presence or absence 
of Epo did not have an effect on the level of apoptosis (Fig. 4 A, 
23.6% FN + Epo vs. 18.7% PBS + Epo and 39.9% FN-Epo vs. 
42.0% PBS-Epo).
To test the role of Epo and fi  bronectin in preventing apop-
tosis during the second phase of erythropoiesis, TER119
− pro-
genitors were cultured overnight on uncoated substrates with 
Epo as in Fig. 4 A and were transferred to fresh fi  bronectin or 
control substrates in the absence of Epo. 4 h after Epo removal, 
28.8% of the cells from control wells were annexin V positive 
Figure 2.  Fibronectin supports the expansion of erythroid progenitors. 
TER119
− fetal liver erythroid progenitor cells were cultured on ﬁ  bronectin 
or control (uncoated) substrates with Epo-containing media for 1 d and 
then in Epo-free media for a second day. At days 1 and 2, the number of 
live cells was counted. Progenitor cells cultured on ﬁ  bronectin  undergo 
dramatic expansion in cell number, but cells cultured on a control substrate 
do not. Each point is the mean of three to ﬁ  ve independent experiments. 
Error bars represent the SD.
Figure 3.  Fibronectin is only required on the second day of culture. 
(A) TER119
− erythroid progenitors were cultured on either ﬁ  bronectin or 
uncoated surfaces for 1 d in Epo-containing media and were dissociated 
and transferred to fresh ﬁ  bronectin surfaces in Epo-free media. A dramatic 
expansion in cell number was observed regardless of which substrate was 
present on the ﬁ  rst day of culture. (B) TER119
+ cells were cultured on ﬁ  bro-
nectin or uncoated surfaces in the absence of Epo. Only those cells cul-
tured on ﬁ  bronectin proliferate; the addition of Epo to the culture media 
(dashed line) had no effect on cell number. Each point is the mean of three 
to ﬁ  ve independent experiments. Error bars represent the SD.JCB • VOLUME 177 • NUMBER 5 • 2007  874
versus 17.1% of those on fi  bronectin (Fig. 4 B). Thus, the pres-
ence of fi  bronectin during the second phase partially protects 
erythroid cells from apoptotic death.
One of the mechanisms of apoptosis protection mediated by 
Epo is through up-regulation of the antiapoptotic protein bcl-xL 
(Socolovsky et al., 1999), so we tested whether fi  bronectin pro-
tects against apoptosis in a similar manner in the second phase of 
erythropoiesis. TER119
− progenitors were cultured overnight on 
uncoated substrates in the presence of Epo and were serum starved 
for 1 h before being transferred to fresh fi  bronectin or control 
substrates in the absence of Epo. Cells were lysed at 30 min, and 
bcl-xL protein expression was assessed via Western blotting. As 
shown in Fig. 5 (A and B), bcl-xL expression is distinctly higher 
in cells cultured on fi  bronectin than in those cultured in control 
wells. Similar results were obtained via quantitative PCR as well 
as fl  ow cytometry (unpublished data). These data support the idea 
that fi  bronectin induces signals that act to prevent apoptosis in the 
second phase of erythropoiesis, much like the binding of Epo to 
its receptor does in the fi  rst phase.
Erythroid cells express ﬁ  bronectin 
receptors 𝗂4𝗃1 and 𝗂5𝗃1 integrins
We were interested in determining the molecular mediators of the 
observed fi  bronectin response, so we focused on integrins as 
fi  bronectin receptors. As previously shown, E14.5 fetal liver cells 
can be separated into fi  ve distinct phases of erythroid develop-
ment on the basis of the relative expression of CD71 and TER119 
(Fig. 1 A; Zhang et al., 2003). This system allowed us to examine 
the expression of candidate fi  bronectin receptors at distinct phases 
in erythropoiesis that correlate with our two-phase model.
We used fl  ow cytometry to determine fi  bronectin receptor 
expression on the surface of fetal liver erythroid progenitors. 
By costaining E14.5 fetal liver cells with antibodies to CD71 
and TER119 as well as a panel of integrin subunits, we deter-
mined that α4, α5, and β1 are the most highly expressed integ-
rins on these cells. The expression of α2, αv, β2, and β3 integrins 
Figure 4.  Epo and ﬁ  bronectin protect against apoptosis. (A) TER119
− progenitor cells were cultured overnight on ﬁ  bronectin or uncoated substrates in the 
presence or absence of Epo. Annexin v binding (shown on the y axis) was assayed via ﬂ  ow cytometry, and the percentage of positive cells is indicated in 
each plot. The absence of Epo during the ﬁ  rst day of culture leads to an increase in the percentage of apoptotic cells, but the absence of ﬁ  bronectin does 
not have an effect. (B) Fibronectin protects from apoptosis in the second stage of proliferation. TER119
− progenitor cells were cultured overnight on un-
coated surfaces in the presence of Epo and were dissociated and transferred to fresh ﬁ  bronectin or control surfaces in Epo-free media. Annexin v binding 
was assayed at 4 h. The absence of ﬁ  bronectin in the second phase of culture led to an increased percentage of annexin v–positive cells. These data are 
representative of three to ﬁ  ve independent experiments.
Figure 5.  Fibronectin up-regulates bcl-xL in the second stage. TER119
− 
progenitor cells were cultured overnight on uncoated surfaces in the pres-
ence of Epo and were dissociated and serum starved for 1 h before being 
transferred to fresh ﬁ  bronectin or control surfaces in Epo-free media. bcl-xL 
expression was assayed at 30 min via Western blotting. (A) Representative 
Western blot indicating the up-regulation of bcl-xL on ﬁ  bronectin and the 
equivalent expression of actin as a loading control. The anti-actin and 
anti–bcl-xL antibodies were raised in different hosts, thereby allowing the 
visualization of both proteins on the same membrane. (B) Quantiﬁ  cation of 
ﬁ  ve identical experiments. Integrated ﬂ  uorescence intensity on the control 
substrate was normalized to that on ﬁ  bronectin, indicating a statistically 
signiﬁ  cant decrease in the absence of ﬁ  bronectin. *, P ≤ 0.01. Error bars 
represent the SD.INTEGRINS IN RED CELL DEVELOPMENT • ESHGHI ET AL. 875
was not distinguishable from the background fl  uorescence on 
erythroid progenitor R1 and R2 cells, a pooled population of 
progenitors we refer to as R1 + R2 cells (unpublished data). 
The expression of α4, α5, and β1 integrins is down-regulated as 
cells differentiate (Fig. 6). R1 + R2 cells express the highest 
levels of each integrin subunit, and the expression levels in the 
R3, R4, and R5 populations progressively decrease. Although R4 
and R5 cells have completely lost the expression of α5 integrin, 
the expression of α4 and β1 integrins is clearly distinct from the 
background in these populations.
Adhesion to ﬁ  bronectin is correlated 
with integrin receptor expression
To test the functional role of the loss of integrin expression 
on fetal liver erythroid cells, we adapted a quantitative cell–
extracellular matrix adhesion assay for use with the fetal liver ery-
throid system. A centrifugation assay is ideal for this application 
because it is highly quantitative and repeatable while requiring 
no special equipment (Hertl et al., 1984). Using this assay, we 
demonstrated a progressive loss in adhesion to fi  bronectin dur-
ing erythroid development (Fig. 7 A). Sorted R1–5 cells were 
allowed to attach to plates coated with 10 or 3 μg/ml human 
plasma fi  bronectin and were centrifuged at an acceleration of 
 1,000 g. Whereas 75% of R1 + R2 cells adhere to 10 μg/ml 
fi  bronectin under these conditions, the fraction of adherent cells 
decreases progressively in the R3–5 populations. Adhesion 
of all cell populations was greater on 10 μg/ml fi  bronectin than 
on 3 μg/ml. The progressive decrease in adhesion on fibro-
nectin parallels the loss of α4-, α5-, and β1-integrin expression 
shown in Fig. 6.
The optimum centrifugal force for cell detachment was 
determined by applying a range of centrifugal accelerations to 
R1 + R2 and R5 cells attached to plates coated with 10 μg/ml 
fi  bronectin (Fig. 7 B). A low centrifugal force was not enough 
to distinguish between R1 + R2 and R5 cell populations, 
whereas higher forces removed all of the R5 cells. A centri-
fugal acceleration of 1,000 g provided enough force to distin-
guish between the adhesion of R1 + R2 and R5 cells without 
removing all of the R5 cells; thus, 1,000 g was used for all 
further studies.
Role of integrins in adhesion 
of erythroid progenitors
To test the role of specifi  c integrin subunits in mediating adhesion 
to fi  bronectin, we used recombinant fi  bronectin fusion proteins. 
These recombinant proteins contain either the α4β1-binding 
site (VRGD
−), the α5β1-binding site (Vo), or both binding sites 
(V; Fig. 8 A). Cell adhesion assays were performed as in Fig. 7. 
Figure 7.  Adhesion to ﬁ  bronectin is correlated with integrin receptor 
expression. (A) Adhesion of R1 + R2, R3, R4, and R5 cells to either 10 (left) 
or 3 μg/ml (right) human plasma ﬁ  bronectin at an acceleration of  1,000 g. 
Cells from each population were sorted and allowed to adhere to ﬁ  bronectin-
coated plates for 30 min before the adhesion assay. Adhesion to ﬁ  bronectin 
decreases as cells differentiate. (B) Adhesion of R1 + R2 and R5 cells to 
10 μg/ml ﬁ  bronectin at a range of centrifugal accelerations. (A and B) In 
all cases, each bar represents the mean fraction adherent from three wells, 
and error bars represent the SD. *, P ≤ 0.05; **, P ≤ 0.01 when com-
pared with R1 + R2 cells. 
Figure 6.  Erythroid progenitors express ﬁ  bronectin receptors. α4, α5, and 
β1 integrins are highly expressed on early erythroid progenitors, and expres-
sion is down-regulated as cells differentiate. Fetal livers were stained with 
antibodies against CD71, TER119, and each of α4, α5, and β1 integrins. 
Cells were gated into regions as in Fig. 1 A, and integrin expression within 
each population was determined. The light trace is the background staining 
of the secondary antibody alone. These data are representative of at least 
three experiments. The horizontal bars represent the fraction of the popula-
tion with integrin expression above the level of the background control.JCB • VOLUME 177 • NUMBER 5 • 2007  876
As shown in Fig. 8 B, adhesion to all fragments mirrors that on 
fi  bronectin in that the fraction of adherent cells on V, Vo, and 
VRGD
− decreases progressively in R1 + R2, R3, R4, and R5 
populations. For all populations of cells, adhesion was greatest 
to the V fragment, which contains both α4β1- and α5β1-integrin–
binding sites.
We then repeated the adhesion assay with the addition of 
function-blocking antibodies. Sorted R1 + R2 cells were incu-
bated with function-blocking antibodies to α4 or α5 integrin be-
fore being added to precoated plates. When α4 integrins were 
blocked on R1 + R2 cells, adhesion to the α4β1-binding frag-
ment VRGD
− was almost completely abrogated, whereas adhe-
sion to the α5β1-binding fragment Vo was unaffected (Fig. 8 C). 
Similarly, blocking α5 integrins on R1 + R2 cells had no effect 
on cell adhesion to α4β1-binding fragments but abrogated adhe-
sion to α5β1-binding fragments. These results indicate that α4β1 
and α5β1 integrins on fetal liver erythroid progenitor cells medi-
ate adhesion to distinct sequences on fi  bronectin.
Changes in the levels of integrin expression and corre-
sponding adhesion to fi  bronectin is physiologically relevant, as 
erythroid progenitors and erythroblasts must be retained in the 
bone marrow or fetal liver, whereas the more differentiated re-
ticulocytes must be released into the circulation. Because fi  bro-
nectin is a major extracellular matrix protein in both the fetal 
liver and bone marrow, we conclude that adhesion of erythroid 
progenitors by both α4β1 and α5β1 integrins is crucial in retain-
ing immature erythroid cells in the marrow, and loss of these 
integrins is likely crucial in triggering their release.
𝗂4 but not 𝗂5 integrin mediates 
the ﬁ  bronectin response
We were interested to determine whether both α4β1 and α5β1 
integrins were responsible for the observed proliferative and 
antiapoptotic effects of fibronectin in the second phase of 
erythropoiesis. To this end, we cultured TER119
− erythroid 
progenitors on the various recombinant fi  bronectin fragments in 
Epo-containing media for 1 d and then in Epo-free media for 
a second day. Importantly, only those cultured on α4β1-binding 
substrates V and VRGD
− underwent a dramatic expansion be-
tween days 1 and 2 similar to cells cultured on intact fi  bronectin 
(Fig. 9 A). In contrast, cells cultured on the α5β1-binding frag-
ment Vo exhibited a defect in cell expansion, indicating that 
α4β1-mediated adhesion to fi  bronectin is necessary for maximum 
numbers of terminal erythroid divisions.
We obtained the same result when we blocked integrin 
engagement with antibodies. TER119
+ cells were isolated from 
the fetal liver as in Fig. 3 B and were incubated with function-
blocking antibodies against α4 or α5 integrins for 15 min on ice. 
Cells were then added to fi  bronectin-coated or control plates in 
Epo-free media. As shown in Fig. 9 B, blocking α4 integrin 
blocked expansion signifi  cantly on fi  bronectin (P = 0.0023). 
Blocking α5 integrin had a lesser effect.
Our two-phase model of erythroid expansion predicts that 
α4β1-integrin engagement is only necessary during the second, 
Epo-independent phase. We tested this prediction by varying the 
extracellular matrix cues presented to the cells during the fi  rst 
and second phases of culture, as in Fig. 3 B. As seen in Fig. 9 C, 
cells cultured on the α5β1-binding substrate Vo for the first 
day exhibit normal expansion when transferred to α4β1-binding 
substrates (fi  bronectin and VRGD
−) for the second day. Con-
versely, there is a marked defect in expansion if cells are cul-
tured in the absence of α4β1-mediated adhesion on the second 
day even if α4β1 integrin is engaged during the fi  rst day of cul-
ture (Fig. 9 D). Collectively, these results indicate that the pro-
liferative effect of fi  bronectin on the second day of erythropoiesis 
is α4β1 integrin dependent.
We went on to characterize the role of α4β1 integrin in pre-
venting the apoptosis of differentiating erythroid cells. TER119
− 
progenitor cells were cultured overnight on PBS in the presence 
of Epo and were transferred to fresh fi  bronectin or PBS wells in 
the presence or absence of function-blocking antibodies to α4 
and α5 integrins. Blocking α4 integrin increased the percentage 
of annexin V–positive cells 4 h after Epo removal, whereas 
blocking α5 integrin had little effect on the percentage of apoptotic 
cells (Fig. 10). Representative fl  ow cytometry data are shown 
in Fig. 10 A, and the normalized means of three independent 
Figure 8.  Role of integrins in the adhesion of 
erythroid progenitors. (A) Schematic diagram 
of recombinant ﬁ  bronectin fusion proteins. The 
V fragment contains both the α4β1- and α5β1-
binding sites, Vo contains only the α5β1-binding 
site, VRGD
− contains only the α4β1-binding 
site, and VoRGD
− contains neither integrin-
binding site. (B) Characterization of the adhe-
sion of sorted R1 + R2, R3, R4, and R5 cells to 
10 μg/ml V, Vo, or VRGD substrates at an 
acceleration of  1,000 g. (C) α4β1 and α5β1 
integrins mediate adhesion to different ﬁ  bro-
nectin domains. Adhesion of sorted R1 + R2 
cells to 10 μg/ml recombinant ﬁ   bronectin 
fragments Vo or VRGD
− with and without pre-
treatment with function-blocking antibodies 
to α4 and α5 integrins. Each bar represents the 
mean fraction of cells adherent in each of three 
replicate wells. In all cases, error bars are the SD. 
*, P ≤ 0.05; **, P ≤ 0.01.INTEGRINS IN RED CELL DEVELOPMENT • ESHGHI ET AL. 877
experiments are shown in Fig. 10 B. Collectively, these results 
establish that α4β1 integrin protects differentiating erythroid 
cells from apoptosis much like the action of Epo on early eryth-
roid progenitors.
Discussion
Over the course of erythroid differentiation, progenitor cells 
undergo three to fi  ve cell divisions, during which they undergo 
profound morphological and biochemical changes. These in-
clude up-regulation of the cell surface transferrin receptor CD71, 
which is required for import of the iron essential for hemoglobin 
function, followed by the induction of many erythroid-important 
enzymes and other proteins, including α and β globin; red cell–
specifi  c membrane proteins such as glycophorin, TER119, and 
the anion exchange protein AE1 (also called Band III); and en-
zymes in the heme biosynthetic pathway. Subsequently, during 
the fi  nal two or three cell divisions, there is a marked decrease in 
cellular volume, increase in chromatin condensation, and inacti-
vation of DNA transcription before the fi  nal steps of enucleation 
and expulsion of other organelles (Fawcett, 1997). These changes 
are used to defi  ne the sequential stages of erythroid differentia-
tion: proerythroblasts, basophilic, and polychromatophilic ery-
throblasts, orthochromatic erythroblasts, and reticulocytes. We 
have used the sequential developmental up-regulation of CD71, 
the induction of TER119, and the down-regulation of CD71 as 
a tool for monitoring these stages of erythroid differentiation by 
FACS analysis both during culture in vitro and in vivo (Socolovsky 
et al., 2001; Zhang et al., 2003).
Epo and its specifi  c receptor are crucial for promoting the 
survival, proliferation, and differentiation of mammalian eryth-
roid progenitors (Richmond et al., 2005). The fi  rst stage of 
erythroid differentiation, from CFU-E to late basophilic eryth-
roblast, is highly Epo dependent, whereas differentiation be-
yond this stage is no longer dependent on Epo (Koury and 
Bondurant, 1988). Consistent with this, Epo receptors are lost 
as erythroid progenitors undergo terminal proliferation and 
  differentiation (Zhang et al., 2003). In our culture system for 
primary fetal liver erythroid progenitors, Epo is required only 
during the fi  rst day, when the progenitors undergo the approxi-
mately two initial divisions, and is not essential for the later 
stages of terminal cell proliferation and differentiation. This raises 
the question of what extracellular signals, if any, these differen-
tiating erythroblasts require to support terminal proliferation, 
differentiation, and enucleation.
The main point of this study is that engagement of α4β1 
integrin by fi  bronectin provides signals necessary for the terminal 
expansion of these differentiating erythroblasts. Our experiments 
indicate that erythroid expansion proceeds in two temporally dis-
tinct phases, the fi  rst governed by the binding of Epo to its receptor 
and the second by engagement of α4β1 integrin by fi  bronectin. 
In each phase, Epo and fi  bronectin act to promote cell expan-
sion by inducing antiapoptotic signals through bcl-xL, but it is 
likely that both induce and repress the expression of many other 
genes as well.
Although fi  bronectin is known to be the major extracellular 
matrix protein in the erythroid niche, its role in erythropoietic 
Figure 9.  𝗂4 integrin supports terminal proliferation. (A) α4β1-Mediated 
adhesion is required for the proliferation of differentiating fetal liver ery-
throid cells. TER119
− fetal liver erythroid progenitor cells were cultured on 
V, Vo, VRGD
−, or VoRGD
− substrates with Epo-containing media for 1 d 
and then in Epo-free media for a second day. At days 1 and 2, the number 
of live cells was counted. Only α4β1-binding substrates V and VRGD support 
an expansion in cell number similar to that seen on intact ﬁ  bronectin. α5β1-
Binding substrate Vo supports a moderate level of expansion, and VoRGD, 
which does not engage either integrin, does not support any cell expansion. 
(B) Blocking α4 integrin with an antibody blocks proliferation. TER119
+ cells 
were isolated and incubated with function-blocking antibodies to either 
α4 or α5 integrin and were cultured on ﬁ  bronectin-coated or control substrates 
for 1 d. The mean normalized increase in cell number from three experi-
ments is shown. *, P ≤ 0.05; **, P ≤ 0.01. (C and D) Expansion of ery-
throid progenitors during the second day occurs only in conditions in which 
α4β1 is engaged. TER119
− cells were cultured on Vo (C) or VRGD
− (D) sub-
strates in Epo-containing media for the ﬁ  rst day and were dissociated and 
transferred to wells coated with each of the various integrin-binding sub-
strates in Epo-free media for a second day. Error bars represent the SD.JCB • VOLUME 177 • NUMBER 5 • 2007  878
differentiation and survival was unknown. We used our estab-
lished in vitro model of fetal erythropoiesis to systematically 
vary the extracellular matrix and growth factor cues presented to 
erythroid progenitors. Our experiments indicate that withdrawal 
of Epo during the fi  rst day of the culture period leads to defects in 
cell expansion resulting from increased apoptosis (Figs. 2 and 4 A). 
In contrast, the presence or absence of Epo on the second day 
of culture had no effect on the extent of expansion of these 
more differentiated erythroid cells (Fig. 4 B). Fibronectin plays 
a reciprocal role in that it has no effect on the survival or expan-
sion of early erythroid CFU-E progenitors, but its absence on the 
second day of culture leads to increased apoptosis and a reduc-
tion in cell division (Figs. 2, 3 B, and 4 B). These results estab-
lish that erythropoiesis is governed by an early Epo-dependent 
phase followed by a later fi  bronectin-dependent phase.
To determine the molecular mediators of the observed 
fi  bronectin response, we measured integrin expression levels in 
erythroid progenitor cells; on these cells, α4, α5, and β1 were the 
mostly highly expressed integrins. Furthermore, we showed a 
progressive down-regulation of α4, α5, and β1 integrins over the 
3-d course of erythroid differentiation (Fig. 6). A quantitative 
adhesion assay indicated that the loss of integrin expression is 
correlated with the loss of adhesion to fibronectin (Fig. 7 A). 
Changes in the levels of integrin expression and corresponding 
adhesion to fi  bronectin are physiologically relevant, as erythroid 
progenitors and erythroblasts must be retained in the bone marrow 
or fetal liver, whereas the more differentiated reticulocytes must be 
released into the circulation. In this respect, α4 and α5 integrins 
play a similar role in that they both function as adhesion recep-
tors (Fig. 8 B). Because fi  bronectin is a major extracellular ma-
trix protein in the bone marrow, we conclude that adhesion of 
erythroid progenitors by both α4β1 and α5β1 integrins is crucial 
in retaining immature erythroid cells in the marrow, and the loss 
of these integrins is likely crucial in triggering their release.
By culturing erythroid progenitor cells on recombinant 
fi  bronectin fragments, we demonstrated that only α4β1-integrin 
engagement supports expansion on fibronectin-coated sur-
faces (Fig. 9 A), indicating that α4 integrins play an additional 
role in transducing signals from the extracellular matrix. A 
previous study has identifi  ed α4β1 and α5β1 as the predomi-
nant integrins on erythroid progenitors (Rosemblatt et al., 
1991), but in the present study, for the first time, we distin-
guish between the roles of these two fi  bronectin receptors on 
erythroid cells.
As predicted by our two-phase model, α4β1-integrin en-
gagement is necessary only during the second phase of erythro-
poiesis, when erythroblasts undergo the approximately two fi  nal 
cell divisions and enucleate. As shown in Fig. 9 (B and C), 
  robust cell expansion is observed when α4β1-integrin engagement 
is provided in the second, Epo-independent phase of the culture 
period regardless of whether fi  bronectin or any of its fragments 
was present during the fi  rst, Epo-dependent phase. Thus, our 
work suggests that α4β1 integrin plays two roles in erythroid 
development. In the fi  rst phase of development, α4β1 seems to 
function solely as an adhesion receptor for fi  bronectin, whereas 
in the second phase, it functions to activate pathways that are 
necessary for erythroid expansion.
Interestingly, we found that integrin engagement is not 
essential for the differentiation of erythroid progenitors, as mea-
sured by the expression levels of CD71 and TER119 (unpublished 
data), supporting the view that erythroid differentiation and ex-
pansion are decoupled and regulated by separate pathways 
(Arroyo et al., 1999). Withdrawal of Epo during the fi  rst phase 
of erythropoiesis and the lack of engagement of α4β1 integrin 
during the second phase both lead to increased apoptosis. Dead 
cells cannot proliferate or differentiate, and, thus, it is diffi  cult 
to determine whether signals downstream of the Epo receptor or 
α4β1 integrin directly activate signal transduction pathways 
leading to cell proliferation or differentiation. Alternatively, by 
preventing apoptosis, these signals could allow previously in-
scribed signaling pathways to support both the cell division and 
induction of erythroid-specifi  c genes.
Figure 10.  𝗂4 integrin provides protection from 
apoptosis. (A) α4 integrin engagement provides pro-
tection from apoptosis in the second phase. TER119
− 
fetal liver cells were puriﬁ  ed and cultured overnight on 
uncoated substrates in Epo-containing media. Cells 
were then dissociated, incubated with or without anti-
bodies to α4 or α5 integrins, and cultured in Epo-free 
media on ﬁ  bronectin or control substrates. 4 h after Epo 
removal, the cells were dissociated and stained with 
annexin V and 7-AAD to assay for apoptosis. Annexin V 
binding is shown on the y axis. Data are representa-
tive of three independent experiments. The percentage 
of positive cells is indicated in each plot. (B) Summary 
of apoptosis data. Error bars represent the SD. *, P ≤ 
0.05; **, P ≤ 0.01.INTEGRINS IN RED CELL DEVELOPMENT • ESHGHI ET AL. 879
In other systems, cytokine and integrin-mediated signals 
interact to direct cell behavior. For example, the differentiation 
of mammary epithelia requires signals initiated by the binding 
of prolactin to its receptor as well as the simultaneous engage-
ment of β1 integrins by the basement membrane protein laminin 
(Streuli et al., 1995). Similar coordination is evident in neuro-
genesis, in which simultaneous signals from FGF and β1 integrins 
are necessary for neural stem cell maintenance and proliferation 
(Campos, 2005). One important distinction of these developmental 
pathways with erythroid development is that growth factor and 
integrin-mediated signals regulate erythroid cells at very different 
stages of differentiation, whereas in these other systems, they 
occur simultaneously.
Integrin-mediated adhesion to the extracellular matrix 
initiates a diverse set of intracellular signaling pathways that 
are specifi  c to each integrin dimer and cell type. Little is known 
about the precise downstream pathways activated after integ-
rin receptor–ligand binding in erythroid cells. In fi  broblasts, 
integrin engagement often results in the formation of focal 
adhesions, which form linkages to the cytoskeleton and bring 
together many different scaffolding proteins and enzymes to 
activate downstream signaling pathways such as MAPK and 
Ras (Wozniak et al., 2004). Although focal adhesion kinase 
(FAK) has emerged as the key signaling component of focal 
adhesions, our preliminary data and that of others suggest that 
the FAK family member PYK2 rather than FAK itself is acti-
vated in erythroid cells in response to integrin activation 
(Avraham et al., 2000). Identifying the downstream signaling 
pathways and transcription factors that are activated by integrin-
mediated adhesion in these cells is one important area for 
future work. In addition, examining any interaction between 
Epo- and integrin-mediated signals would provide additional 
insight into the regulation of erythroid development. For 
  example, it is likely that Epo-mediated signals during the fi  rst 
day of proliferation and differentiation of erythroid progeni-
tors generate cells that are primed to receive and transduce 
  integrin-mediated signals during the fi  nal days of erythropoiesis. 
In particular, signals activated downstream of the Epo receptor 
may affect integrin activation. Determining how α4β1 integrin 
affects apoptosis and cellular expansion and how these signals 
are integrated with Epo-mediated signals is the focus of our 
future work.
Materials and methods
Animals
C57BL/6 mice were purchased from The Jackson Laboratory and main-
tained at the Whitehead Institute animal facility.
Fetal liver erythroid progenitor cells
C57BL/6 E14.5 fetal livers were dissected into Hank’s Balanced Salt Solu-
tion containing 2% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 
and 10 mM Hepes, pH 7.4 (called HBSS+) at a concentration of two livers 
per milliliter. Liver tissue was disaggregated by vigorous pipetting followed 
by passage though a 70-μm cell strainer. Cells were blocked with a 1:50 
dilution of ChromPure Rat IgG (The Jackson Laboratory) and labeled with 
a 1:200 dilution of phycoerythrin TER119 and FITC CD71 antibodies (BD 
Biosciences) for 15 min on ice. Cells were washed and resuspended in 
HBSS+ and labeled with 1 μg/ml propidium iodide for cell sorting on a 
MoFlow3 cell sorter (Becton Dickinson).
In vitro erythroid culture
Fetal liver differentiation assays were performed as previously described 
(Zhang et al., 2003). In brief, day 14.5 fetal livers were suspended in PBS + 
2% FBS at a concentration of two fetal livers/milliliter. Cells were incu-
bated with 1:50 rat IgG for 15 min on ice followed by 1:100 biotinylated 
anti-Ter119 antibody (BD Biosciences). Cells were washed, resuspended at 
the same concentration, and further labeled with 1:10 tetrameric streptavidin 
complex (StemCell Technologies) for 15 min followed by 60 μl of mag-
netic  colloids per milliliter of cells (StemCell Technologies) for 15 min. 
Ter119
− cells were puriﬁ  ed using a StemSep magnetic column (StemCell 
Technologies) according to the manufacturer’s instructions. Cells were then 
seeded into 24-well plates coated overnight with 0.5 ml of 20 μg/ml human 
plasma ﬁ  bronectin, V, Vo, or VRGD
− recombinant fusion proteins and 
washed twice with PBS. Cells were seeded at a density of 100,000 cells/ml. 
For the ﬁ  rst 16–18 h, they were cultured in day 1 media, which consists 
of Iscove’s Modiﬁ   ed Dulbecco’s Medium (Invitrogen) supplemented with 
15% FBS (StemCell Technologies), 1% BSA (StemCell Technologies), 10 μg/ml 
recombinant human insulin (Sigma-Aldrich), 200 μg/ml recombinant human 
holotransferrin (Sigma-Aldrich), 10
−4 M β-mercaptoethanol, 1% penicillin/
streptomycin, 2 mM glutamine, and 2 U/ml Epo (Amgen). After 16–18 h, 
the medium was changed to day 2 media, which consists of Iscove’s Modi-
ﬁ  ed Dulbecco’s Medium supplemented with 20% FBS (Invitrogen), 10
−4 M 
β-mercaptoethanol, 1% penicillin/streptomycin, and 2 mM glutamine. At 
each time point, cells were dissociated with PBS containing 5 mM EDTA and 
10% FBS for 5 min at 37°C. Cells were counted using a hemocytometer 
(BrightLine; Hausser Scientiﬁ  c) and were stained with 1:200 FITC CD71 and 
phycoerythrin TER119 for 15 min on ice. Cells were washed and analyzed 
used a ﬂ  ow cytometer (FACSCalibur; Becton Dickinson). FACS data were 
analyzed using FlowJo 6.0 software (Tree Star, Inc.).
 In experiments in which the substrate was varied from days 1 to 2, 
cells were cultured in day 1 media for the ﬁ  rst day, dissociated with PBS 
containing 5 mM EDTA and 2% FBS for 5 min at 37°C, counted using the 
BrightLine hemocytometer, and added to fresh plates coated with 20 μg/ml 
human plasma ﬁ  bronectin, Vo, or VRGD
− recombinant fusion proteins in 
day 2 media. After 24-h culture, cells were dissociated and counted.
 In experiments using TER119
+ cells, E14.5 fetal livers were blocked 
and labeled with biotinylated TER119 antibody. Cells were then washed, 
resuspended in HBSS+, and incubated with streptavidin-coupled micro-
beads (Miltenyi Biotec) according to the manufacturer’s instructions. 
TER119
+ cells were isolated on an autoMACS column (Miltenyi Biotec) using 
the Possel_s program.
Recombinant ﬁ  bronectin proteins
Recombinant ﬁ  bronectin fusion proteins were expressed in Escherichia coli 
grown to late log phase and induced with 1 mM IPTG for 4 h. Cells were 
harvested by centrifugation and stored at –80°C in PBS containing a cock-
tail of protease inhibitors (Sigma-Aldrich). Bacterial pellets were thawed, 
and the buffer was adjusted to 50 mM sodium phosphate, pH 8.0, 10 mM 
imidazole, and 300 mM NaCl. Pellets were incubated with 2 mg/ml lyso-
zyme and DNase for 30 min at 4°C, lysed using a French press, brought 
to 1% Triton X-100, and centrifuged at 20,000 g for 20 min. Supernatants 
were incubated with TALON resin (CLONTECH Laboratories, Inc.) and 
washed in 50 vol of wash buffer (50 mM sodium phosphate, pH 8.0, 300 mM 
NaCl, and 10 mM imidazole), and proteins were eluted with 2 vol of elu-
tion buffer (wash buffer adjusted to 250 mM imidazole). Proteins were dia-
lysed against CAPS buffer (20 mM CAPS, pH 11.0, and 150 mM NaCl). 
The ﬁ  nal protein concentrations were determined by UV absorption, and 
protein sizes were conﬁ  rmed on SDS-PAGE.
Apoptosis assay
To measure apoptosis, TER119
− cells were isolated and cultured on un-
coated surfaces in day 1 media for 16–18 h. At this time, cells were disso-
ciated, washed, and incubated with 10 μg/ml of function-blocking antibodies 
to either α4 (clone PS/2; Serotec) or α5 (5H10-27; BD Biosciences) integrin 
for 15 min on ice. The cells were then transferred to fresh ﬁ  bronectin or 
control substrates in Epo-free day 2 media. 4 h after Epo removal, cells 
were dissociated and stained with annexin V–allophycocyanin (BD Bio-
sciences) and 7-AAD (BD Biosciences) according to the manufacturer’s 
  instructions. bcl-xL expression was assayed by ﬁ  xing and permeabilizing 
the cells and staining with 1:500 antibody to bcl-xL (clone 54H6; Cell Signal-
ing Technology) for 15 min at room temperature followed by 1:1,000 
AlexaFluor647 secondary antibody for 15 min at room temperature (Invit-
rogen). Expression data were then collected on a ﬂ  ow cytometer (FACS-
Calibur; BD Biosciences) and analyzed using FlowJo software. Cells were 
gated based on forward scatter and side scatter properties before then 
analyzing annexin v and 7-AAD levels.JCB • VOLUME 177 • NUMBER 5 • 2007  880
Integrin staining
C57/Bl6 E14.5 fetal livers were dissected and stained as above with the 
addition of a 1:100 dilution of the following biotinylated antiintegrin anti-
bodies, which were all obtained from BD Biosciences: α4 (9C10), α5 
(5H10-27), and β1 (Ha2/5). Cells were washed, resuspended, and stained 
with 1:1,000 streptavidin phycoerythrin Cy5.5 (Caltag Laboratories) for 
15 min on ice. Cells were washed, resuspended in HBSS+, and labeled 
with 1 μg/ml propidium iodide for FACS analysis. Data were collected on 
a cell sorter (MoFlow3; Becton Dickinson) and analyzed with FlowJo 6.0 
software (Tree Star, Inc.).
Adhesion assays
96-well half-area plates (Costar) were precoated with various concentra-
tions of human plasma ﬁ  bronectin (Sigma-Aldrich) diluted in PBS overnight 
at 4°C and washed twice with PBS before cell seeding. 5,000 freshly sorted 
fetal liver R1–5 erythroid progenitors were resuspended in 100 μl Alpha 
Modiﬁ  ed Essential Medium (Invitrogen) and added to each well. Cells were 
incubated at 37°C for 30 min. To perform the adhesion assay, wells were 
ﬁ  lled to the top with medium and covered with clear sealing tape (Costar), 
ensuring no entrapped air bubbles. Plates were inverted and spun at the 
various speeds for 5 min. Each well was photographed, and the number of 
cells was enumerated before and after spinning. Fraction adherent was cal-
culated as the number of cells present in each well after spinning divided by 
the number of cells present before spinning. Cells were enumerated using 
ImageJ image analysis software (National Institutes of Health).
 The force experienced by the cells is given by the following 
equation:
 
=´ ´ r - r
µw ´ 2
() cell cell medium
c
FR C F V
RCF r
  
where V is the volume of the cell, ρcell is the density of the cell, ρmedium is the 
density of the medium, RCF is the relative centrifugal force, ω is the centrifu-
gal velocity, and rc is the radius of the centrifugation. In our centrifuge, 
rc was 10 cm.
For integrin inhibition studies, cells were incubated with 10 μg/ml 
of the following function-blocking antibodies before cell seeding: α4 clone 
PS/2 (Serotec), α5 clone 5H10-27 (BD Biosciences), and β1 clone Ha2/5 
(BD Biosciences). Cells were stained for 30 min at 37°C.
Statistical analysis
Signiﬁ  cance levels were determined using the t test algorithm in Excel 
(Microsoft). For the data in Figs. 5, 8 (B and C), 9 B, and 10 B, a homosce-
dastic two-tailed distribution was used. In Fig. 7 (A and B), a heteroscedastic 
two-tailed distribution was used.
bcl-xL expression
TER119
− cells were isolated and cultured in day 1 media on uncoated 
surfaces overnight. Cells were then dissociated and serum starved in 
Iscove’s Modiﬁ  ed Dulbecco’s Medium + 1% BSA for 1 h before being 
transferred to fresh ﬁ  bronectin or uncoated wells. At the indicated time 
points, cells were lysed in modiﬁ  ed radioimmunoprecipitation assay buffer 
(50 nM Tris, pH 7.4, 250 nM NaCl, 2 nM EDTA, and 0.5% NP-40) con-
taining protease inhibitors (Complete mini [Roche], 4 mM NaF, and 4 mM 
Na3VO4) for 20 min at 4°C. Lysates were ultracentrifuged at 13,000 g for 
10 min at 4°C and analyzed via SDS-PAGE. Membranes were blocked 
with Odyssey Blocking Buffer (LI-COR Biosciences) for 1 h and incubated 
with 1:1,000 bcl-xL antibody clone 54H6 (Cell Signaling Technology) and 
1:1,000 actin antibody I-19 (Santa Cruz Biotechnology, Inc.) overnight. 
Proteins were visualized using the Odyssey infrared imaging system 
(LI-COR Biosciences).
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